HSBC Eli Lilly (LLY) promotions to keep, the target price is happy to $ 700

Elie Lily and Partners (NYSE:ToHe is one of Best stocks for A 20 -year -old long -term stock portfolio. Elie Lily’s performance was largely weak this year with YTD decreased to more than 5 %. On August 8, her shares touched $ 625 to $ 626, and the last time it was seen in 2024. However, it was estimated nearly 17 % with the improvement of investor morale. August 27, the HSBC Rajesh Kumar analyst to upgrade Eli Lilly and Company (NYSE: LLY) to keep Sell and raised its target price to $ 700 from 675 dollars, citing the advancement of oral weight loss. HSBC, who had previously decreased on the stock, admitted that the Bear case has now played after the results of the positive experience in the late stage.

Myriam Zillles depicting not dye, the experiment showed a significant weight loss in obese patients and type 2 diabetes, as it came before expectations and better performance of oral treatment. This result strengthens Elie Lily’s position in both the United States and foreign markets. The FDA in 2026 and expectations in the streets indicate that the drug can generate $ 15.5 billion of annual sales by 2032. With this upgrade, the majority of analysts now have a purchase classification or its equivalent on Eli Lilly and Compaany (NYSE: LLY), without any sale reviews. The average price of the price for one year from 900 dollars indicates a rise of 23 % of the upward trend. Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that focuses on developing, manufacturing and marketing diabetes, oncology, immunity and neuroscience. While we acknowledge the LLY capabilities as an investment, we believe that some artificial intelligence shares provide greater potential and carry less risks on the negative side. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term. Read the following: The 10 best shares to buy and keep them foreverand 12 large stocks that overlook them with low complications. Detection: Nothing. This article was originally published in A monkey from the inside.